Related Experiment Video
Updated: Apr 22, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Management of NSCLC: focus on crizotinib
Lorenza Landi1, Federico Cappuzzo
1Istituto Toscano Tumori, Medical Oncology Department , Ospedale Civile, viale Alfieri 36, 57100 Livorno , Italy +39 0586223189 ; +39 0586223457 ; f.cappuzzo@gmail.com.
Crizotinib is an effective treatment for Anaplastic Lymphoma Kinase (ALK)-positive non-small cell lung cancer (NSCLC), improving outcomes. However, acquired resistance limits long-term efficacy, necessitating further research into novel ALK inhibitors.
Area of Science:
- Oncology
- Pharmacology
Background:
- Anaplastic Lymphoma Kinase (ALK) translocations define a unique non-small cell lung cancer (NSCLC) subgroup.
- ALK gene fusions are oncogenic drivers and attractive therapeutic targets in NSCLC.
Purpose of the Study:
- To review and analyze data on crizotinib for ALK-positive NSCLC.
- To evaluate crizotinib's efficacy, safety, and resistance patterns.
Main Methods:
- Systematic collection and analysis of preclinical and clinical trial data for crizotinib.
- Review of Phase I, II, and III trial results.
Main Results:
- Crizotinib improves response rate and progression-free survival versus chemotherapy in ALK-positive NSCLC.
- Crizotinib demonstrates activity in previously treated and heavily pretreated populations.
- Crizotinib has a manageable toxicity profile.
Conclusions:
- Crizotinib is a primary treatment for ALK-positive NSCLC patients not previously treated with ALK inhibitors.
- Acquired resistance to crizotinib is common, and optimal management strategies are undefined.
- New ALK inhibitors are under investigation to overcome resistance.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistent Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Cystic Fibrosis: Management
Sinus disease and chronic...